c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity.The mature receptor is made up of the alpha and beta subunits, which are disulfide linked after post-translational cleavage of the primary single chain precursor protein. A membrane receptor called c-Met is crucial for both wound healing and embryonic development. The c-Met receptor's sole known ligand is hepatocyte growth factor (HGF). Cells of epithelial origin typically express c-Met, whereas cells of mesenchymal origin only express HGF. In response to HGF stimulation, c-Met triggers a number of biological processes that together give rise to the invasive growth program.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V0604 | Tivantinib (ARQ 197) | 905854-02-6 | Tivantinib (formerly also known asARQ-197; ARQ197), an experimental drug developed byby Arqule, Inc, is the first non-ATP-competitive, orally bioavailable and selective small molecule c-Met inhibitor with potential antineoplastic activity. |
|
V69323 | Tunlametinib (HL-085) | 1801756-06-8 | Tunlametinib is an anti-tumor compound and a tyrosine kinase inhibitor (TKI). |
|
V5067 | Tyrosine kinase inhibitor | 1021950-26-4 | tyrosine kinase inhibitor (TKI) is a potent tyrosine kinase inhibitor (TKI). |
|
V69322 | Tyrosine kinase-IN-6 | 2377507-01-0 | Tyrosine kinase-IN-6 is a potent and promising inhibitor of RON splice variants with anticancer and anti-tumor activities. |
|
V69320 | Vabametkib | 1571903-56-4 | Vabametkib is a potent inhibitor of hepatocyte growth factor receptor (HGFR). |
|
V79498 | VEGFR-2/c-Met-IN-2 | VEGFR-2/c-Met-IN-2 (compound 3e) is a VEGFR-2/c-Met inhibitor (antagonist) with IC50s of 83 and 48 nM, respectively. | |
|
V69301 | Zongertinib (BI 1810631; BI 764532) | 2728667-27-2 | Zongertinib is a potent tyrosine kinase inhibitor. |
|
V69308 | Zurletrectinib (ICP-723) | 2403703-30-8 | Zurletrectinib is a potent tyrosine kinase (TRK) inhibitor. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
